Pharmaceutical

CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).

Sep 10, 2024 - 04:00
CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).
Read the original article

Tags:

Previous Article

CMN-005 by CoImmune for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of App...

Next Article

CMN-005 by CoImmune for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Group behind ProMED fires three top moderators amid strike

Group behind ProMED fires three top moderators amid strike

Sep 8, 2023

STAT+: Goldman Sachs launches $650 million fund for life sciences investments

STAT+: Goldman Sachs launches $650 million fund for lif...

Jan 4, 2024

Suicides and homicides among young Americans jumped early in the pandemic, study says

Suicides and homicides among young Americans jumped ear...

Jun 16, 2023